|
rs1052501
|
|
Multiple Myeloma
|
|
0.810 |
GeneticVariation
|
BEFREE |
Common single-nucleotide polymorphisms (SNPs) at 2p23.3 (rs6746082), 3p22.1 (rs1052501), 3q26.2 (rs10936599), 6p21.33 (rs2285803), 7p15.3 (rs4487645), 17p11.2 (rs4273077), and 22q13.1 (rs877529) have recently been shown to influence MM risk.
|
24449210 |
2014 |
|
rs10936599
|
|
Multiple Myeloma
|
|
0.810 |
GeneticVariation
|
BEFREE |
Common single-nucleotide polymorphisms (SNPs) at 2p23.3 (rs6746082), 3p22.1 (rs1052501), 3q26.2 (rs10936599), 6p21.33 (rs2285803), 7p15.3 (rs4487645), 17p11.2 (rs4273077), and 22q13.1 (rs877529) have recently been shown to influence MM risk.
|
24449210 |
2014 |
|
rs2285803
|
|
Multiple Myeloma
|
|
0.810 |
GeneticVariation
|
BEFREE |
Common single-nucleotide polymorphisms (SNPs) at 2p23.3 (rs6746082), 3p22.1 (rs1052501), 3q26.2 (rs10936599), 6p21.33 (rs2285803), 7p15.3 (rs4487645), 17p11.2 (rs4273077), and 22q13.1 (rs877529) have recently been shown to influence MM risk.
|
24449210 |
2014 |
|
rs4273077
|
|
Multiple Myeloma
|
|
0.810 |
GeneticVariation
|
BEFREE |
Common single-nucleotide polymorphisms (SNPs) at 2p23.3 (rs6746082), 3p22.1 (rs1052501), 3q26.2 (rs10936599), 6p21.33 (rs2285803), 7p15.3 (rs4487645), 17p11.2 (rs4273077), and 22q13.1 (rs877529) have recently been shown to influence MM risk.
|
24449210 |
2014 |
|
rs4487645
|
|
Multiple Myeloma
|
|
0.810 |
GeneticVariation
|
BEFREE |
Common single-nucleotide polymorphisms (SNPs) at 2p23.3 (rs6746082), 3p22.1 (rs1052501), 3q26.2 (rs10936599), 6p21.33 (rs2285803), 7p15.3 (rs4487645), 17p11.2 (rs4273077), and 22q13.1 (rs877529) have recently been shown to influence MM risk.
|
24449210 |
2014 |
|
rs6746082
|
|
Multiple Myeloma
|
|
0.810 |
GeneticVariation
|
BEFREE |
Common single-nucleotide polymorphisms (SNPs) at 2p23.3 (rs6746082), 3p22.1 (rs1052501), 3q26.2 (rs10936599), 6p21.33 (rs2285803), 7p15.3 (rs4487645), 17p11.2 (rs4273077), and 22q13.1 (rs877529) have recently been shown to influence MM risk.
|
24449210 |
2014 |
|
rs877529
|
|
Multiple Myeloma
|
|
0.810 |
GeneticVariation
|
BEFREE |
Common single-nucleotide polymorphisms (SNPs) at 2p23.3 (rs6746082), 3p22.1 (rs1052501), 3q26.2 (rs10936599), 6p21.33 (rs2285803), 7p15.3 (rs4487645), 17p11.2 (rs4273077), and 22q13.1 (rs877529) have recently been shown to influence MM risk.
|
24449210 |
2014 |
|
rs113488022
|
|
Multiple Myeloma
|
|
0.770 |
GeneticVariation
|
BEFREE |
Finally, rafoxanide had anti-proliferation effect on both wild type and B-Raf V600E mutated MM cells.
|
30583070 |
2019 |
|
rs113488022
|
|
Multiple Myeloma
|
|
0.770 |
GeneticVariation
|
BEFREE |
Previous studies in Western countries demonstrated BRAF V600E mutation only in a small subset of multiple myeloma (MM) patients.
|
29807803 |
2018 |
|
rs113488022
|
|
Multiple Myeloma
|
|
0.770 |
GeneticVariation
|
BEFREE |
Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.
|
27641727 |
2017 |
|
rs113488022
|
|
Multiple Myeloma
|
|
0.770 |
GeneticVariation
|
BEFREE |
We analyzed 121 cases, including 26 HCLs, 52 non-HCL splenic lymphomas, 22 chronic lymphocytic leukemias/small lymphocytic lymphomas (CLLs/SLLs), and 21 plasma cell neoplasms (PCNs) for BRAF V600E expression by IHC.
|
26071465 |
2015 |
|
rs113488022
|
|
Multiple Myeloma
|
|
0.770 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.
|
25794135 |
2015 |
|
rs113488022
|
|
Multiple Myeloma
|
|
0.770 |
GeneticVariation
|
BEFREE |
Targeting the BRAF V600E mutation in multiple myeloma.
|
23612012 |
2013 |
|
rs113488022
|
|
Multiple Myeloma
|
|
0.770 |
GeneticVariation
|
BEFREE |
While no RASSF1A or BRAF mutation (V599E) was detected in any of the primary MM studied (n = 21), the latter was found in the U266 cell line.
|
14616967 |
2003 |
|
rs78311289
|
|
Multiple Myeloma
|
|
0.730 |
GeneticVariation
|
BEFREE |
Cell apoptosis assays were performed in a plasmacytoma cell line, FR4 cells and a myeloma cell line, RPMI8226 cells overexpressing wild-type FGFR3 (FGFR3(WT)) or two different mutants, FGFR3(K650E) or FGFR3(Y373C), and the induction of endoplasmic reticulum (ER) stress protein was compared between each type of cell.
|
21273588 |
2011 |
|
rs78311289
|
|
Multiple Myeloma
|
|
0.730 |
GeneticVariation
|
BEFREE |
Since cell lines may represent useful models for investigating the effects of deregulated FGFR3 mutants in MM, we analysed the expression, activation, signaling pathways and oncogenic potential of three mutants identified so far: the Y373C and K650E in the KMS-11 and OPM-2 cell lines respectively, and the novel G384D mutation here identified in the KMS-18 cell line.
|
11429702 |
2001 |
|
rs78311289
|
|
Multiple Myeloma
|
|
0.730 |
GeneticVariation
|
BEFREE |
Mutation of Lys650-->Glu in the activation loop of the FGFR3 kinase domain causes the lethal human skeletal disorder thanatophoric dysplasia type II (TDII) and is also found in patients with multiple myeloma, bladder and cervical carcinomas.
|
10918587 |
2000 |
|
rs397516896
|
|
Multiple Myeloma
|
|
0.710 |
GeneticVariation
|
BEFREE |
Interestingly, we detected a novel BRAF D594N mutation in one patient with multiple myeloma.
|
21910720 |
2011 |
|
rs72773978
|
|
Multiple Myeloma
|
|
0.710 |
GeneticVariation
|
BEFREE |
Fibroblast growth factor receptor 1 oncogene partner N-terminal like gene (FOPNL) rs72773978 polymorphism was identified as an adverse prognostic factor in multiple myeloma (MM).
|
28691553 |
2018 |
|
rs8058578
|
|
Multiple Myeloma
|
|
0.710 |
GeneticVariation
|
BEFREE |
Two newly identified candidate loci for MM, rs1948915 (8q24.21) and rs8058578 (16p11.2), were nominally associated with MGUS.
|
28375557 |
2017 |
|
rs9344
|
|
Multiple Myeloma
|
|
0.710 |
GeneticVariation
|
BEFREE |
In AL amyloidosis, rs9344 at the splice site of cyclin D1, promoting translocation (11;14), reached the highest significance, P=7.80 × 10<sup>-11</sup>; the SNP was only marginally significant in MM.
|
28025584 |
2017 |
|
rs397507444
|
|
Multiple Myeloma
|
|
0.080 |
GeneticVariation
|
BEFREE |
Our objective was to determine the association between the methylenetetrahydrofolate reductase polymorphisms (C677T and A1298C) and the risk of developing acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and multiple myelomas (MM) in Latinos.
|
31188929 |
2019 |
|
rs397507444
|
|
Multiple Myeloma
|
|
0.080 |
GeneticVariation
|
BEFREE |
Overall, no significant association was found between MTHFR A1298C polymorphism and MM risk under all four genetic models (AC vs. AA, OR = 0.99, 95%CI = 0.82-1.20; CC vs. AA, OR = 1.14, 95%CI = 0.77-1.68; recessive model, OR = 1.10, 95%CI = 0.76-1.59; dominant model, OR = 1.01, 95%CI = 0.84-1.22).
|
26022785 |
2015 |
|
rs397507444
|
|
Multiple Myeloma
|
|
0.080 |
GeneticVariation
|
BEFREE |
Case-control studies investigating associations between multiple myeloma (MM) and the C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) have provided controversial results.
|
18350248 |
2008 |
|
rs397507444
|
|
Multiple Myeloma
|
|
0.080 |
GeneticVariation
|
BEFREE |
We tested whether the polymorphisms of the methylenetetrahydrofolate reductase gene, MTHFR C677T and A1298C, the methionine synthase gene, MTR A2756G, the methionine synthase reductase gene, MTRR A66G, and the thymidylate synthase gene, TYMS 2R-->3R, involved in folate and methionine metabolism, altered the risk for multiple myeloma (MM).
|
17655928 |
2008 |